Annette Colin Lövgren

Annette Colin Lövgren currently works at Initiator Pharma A, as Independent Director from 2021, Colinex Capital AB, as Director from 2008, NorrDia AB, as Director, and ProstaLund AB, as Chief Financial Officer from 2025.
Ms. Colin Lövgren also formerly worked at Trialbee AB, as Chief Financial Officer & Deputy CEO from 2018 to 2019, Annexin Pharmaceuticals AB, as Chief Executive Officer from 2016 to 2017, Biotage GB Ltd., as Director, Boule Medical AB, as Director, Biotage Sweden AB, as Deputy Director, Redsense Medical AB, as Independent Director from 2021 to 2023, SOZAP AB, as Independent Director from 2021 to 2024, Perbio Science AB, as Principal, Biotage AB, as Group Chief Financial Officer from 2020 to 2021, Lindab International AB, as Group Financial Controller, Stille AB, as Chief Financial Officer in 2010, Boule Diagnostics AB, as Group Chief Financial officer from 2022 to 2023, Observe Medical International AB, as Chief Financial Officer, Scandinavian ChemoTech AB, as Chief Financial Officer, Goliath Ltd., as Group Chief Financial Officer, Goliath Holding Plc, as Secretary, and Thunderful Group AB, as Chief Financial Officer.
Ms. Colin Lövgren received her undergraduate degree and graduate degree from the University of Lund.